Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany;Pharmakoökonomisches Modell zur Kosten- Effektivität Topischer Behandlungsformen bei Leichter bis Mittelschwerer Psoriasis Vulgaris in Deutschland

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 4, 2009, Pages 329-338

  Augustin, Matthias ^a   Radtke, Marc ^a   Van Engen, Anke ^b   Ruedig, Cornelia ^b   Lapp, Christina ^c   Moehling, Ulrich ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b IQVIA   (United States)

^c LEO Pharma GmbH   (Germany)

Author keywords

Betamethasone; Calcipotriol; Cost effectiveness; Markov model; Tacalcitol

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; TACALCITOL;

ARTICLE; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; GERMANY; HUMAN; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PHOTOTHERAPY; PROBABILITY; PSORIASIS VULGARIS; STATISTICAL MODEL; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 64249124477     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06919.x     Document Type: Article

References (31)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995 332 : 581 8.
2. Augustin M, Schaefer I, Rustenbach SJ, Zimmer L. Prevalence of skin diseases in a cohort of 48,665 employees in Germany (submitted 2007).
3. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005 64 (Suppl II ii30 ii36.
4. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001 45 : 487 98.
5. van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 2003 16 : 69 83.
6. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, Ruzicka T, van de Kerkhof PCM. Calci-potriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998 139 : 649 54.
7. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997 37 : S55 S58.
8. Molin L, Cutler TP, Elander I, Nyfors B, Downes N and the calcipotriol study group. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Br J Dermatol 1997 136 : 89 93.
9. Fenton C, Plosker GL. Calcipotriol/ Betamethasone Dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol 2004 5 : 463 78.
10. Kaufman R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix F, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B. A new calcipotriol/betamethasone dipropionate formulation (DaivobetTM) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002 205 : 389 93.
11. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kauf-mann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003 48 : 48 54.
12. Douglas WS, Poulin Y, Decroix J, Or-tonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002 82 : 131 35.
13. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionat ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004 150 : 1167 73.
14. ®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006 154 : 1155 60.
15. ®) in the treatment of psoriasis vulgaris. Dermatology 2006 213 : 319 26.
16. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004 151 : 895 7.
17. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998 197 : 31 6.
18. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriasis arthritis in the United States. J Am Acad Dermatol 2002 46 : 850 60.
19. Traupe H, Robra B. Gesundheitsbe-richterstattung des Bundes. Heft 11: Psoriasis. Robert-Koch-Institut Berlin 2002.
20. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006 212 : 137 44.
21. Berger K, Ehlken B, Kugland B, Augu-stin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005 3 : 511 8.
22. ®) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007 215 : 219 28.
23. von der Schulenburg JM, Greiner W. Hannover Guidelines" für die ökonomische Evaluation von Gesundheitsgütern und -Dienstleistungen. In : Pharmakoökonomie in Deutschland (Kori-Lindner C, Hrsg). Aulendorf : Editio Cantor. 1995 225 32.
24. LEO Pharma. Medical departmentsCalcipotriol/betamethasone once daily versus tacalcitol once daily in psoriasis vulgaris. A phase IIIb study with pharmacoeconomic evaluation comparing two treatment regimes in psoriasis vulgaris: i/combination ointment of calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g once daily for 4 weeks followed by calcipotriol ointment 50 μg/g once daily for 4 weeks, with ii/ Tacalcitol ointment 4 μg/g once daily for 8 weeks: 26 November 2002.
25. Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipro-pionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: A randomised, double-blind trial. Dermatology 2004 209 : 308 13.
26. Peeters P, Ortonne JP, Sitbon R, Guig-nard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005 211 : 139 45.
27. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, Ruzicka T, van de Kerkhof PCM. Calci-potriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998 139 : 649 54.
28. Hart-Hansen K, Kjaer T. Eliciting preferences for topical treatment of Psoriasis -An application of the discrete choice experiment. MSc. Thesis for Health Economics, The faculty of Life science, University of Copenhagen, Copenhagen, 25 April 2003 (unpublished).
29. Ashroft DM, Li Wan Po A, Williams HC, Griffiths CE. Cost-Effectiveness Analysis of Topical Calcipotriol versus Short-Contact Dithranol. Pharmacoeconomics 2000 18 : 469 76.
30. Morton CA, Morais JC. Topical combination calcipotriol/betamethasone dipropionate prior to phototherapy in psoriasis - A cost-effective strategy? [PO35.90] 15th Congress of the European Academy of Dermatology and Venereology, 4-8 October 2006, Rhodos, Griechenland.
31. Norregaard J, Lowson D. The cost-utility of calcipotriol/betamethasone (Dovobet) ointment in the treatment of psoriasis vulgaris in the United Kingdom. Value Health 2003 6 : 785.